Matthew Ronsheim
Corporate Officer/Principal en ENTASIS THERAPEUTICS HOLDINGS INC. .
Fortuna: 639 653 $ al 31/05/2024
Perfil
Matthew Ronsheim is currently the Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Prior to this, he was the Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019.
He received his undergraduate degree from Southern Connecticut State University and his doctorate from the University of New Hampshire.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
INNOVIVA, INC.
0.06% | 20/05/2024 | 40 510 ( 0.06% ) | 639 653 $ | 31/05/2024 |
Cargos activos de Matthew Ronsheim
| Empresas | Cargo | Inicio |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 |
Antiguos cargos conocidos de Matthew Ronsheim.
| Empresas | Cargo | Fin |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/08/2019 |
Formación de Matthew Ronsheim.
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Matthew Ronsheim
